Astrazeneca (AZN) said Monday its phase 3b trial of Airsupra asthma rescue therapy showcased statistically meaningful improvements across primary and secondary endpoints in patients with mild asthma compared with albuterol medicine.

The primary efficacy endpoint was the time to first severe asthma exacerbation during the trial. Secondary endpoints involved severe exacerbation rate and usage of total systemic corticosteroids. The trial revealed that Airsupra markedly lowered the risk of a severe exacerbation by 47% compared with albuterol, the company said.

Regarding secondary endpoints, patients on Airsupra had 63% lower exposure to total systemic corticosteroids during treatment versus albuterol alone, reducing risks from cumulative exposure to SCS. Comparable reductions across primary and secondary endpoints were also observed in a prespecified subgroup of adult patients, according to the company.

The trial results show that Airsupra's safety and tolerability were consistent with its safety profile, recording no clinically meaningful changes in safety results between the Airsupra and albuterol groups, according to a statement.

Trial results were presented at the American Thoracic Society 2025 International Conference in San Francisco.

Shares were up nearly 1% in recent trading.

Price: 69.51, Change: +0.70, Percent Change: +1.02